USX:OPGN - OpGen Inc (USD 2.19) OpGen Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance

USD 2.19    -0.020 (-0.90%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


Overview

9 Apr 2020

Day Change: -0.020 (-0.90%)

52 Wk Range: 0.2102 - 12.8

Day's Range: 2.06 - 2.24

Last Volume: 696,646

Current Yield: 0%

Projected Yield: 0%

Open: USD 2.21

9 Apr 2020

Metric OPGN S.Median
Beta 1.77 0.84
VaR 1,095.49 25.23
E.Shortfall 1,095.49 45.03
Liquidity 654.28K 95.2K

Fundamental

9 Apr 2020

PE: -0.282

Market Cap: 3.5M

Price Over Book: 0.816

Price Over Sales: 1

Return On Assets: -119.4%

Return On Equity: -289.9%

Price Over NAV: [Friends Only]

General

CEO: Evan Jones

Headquarters: Gaithersburg

Employees: 48

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

OpGen, Inc. engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings. It helps physicians enhance patient outcomes by providing information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms. The company offers a portfolio of in vitro diagnostic products and clinical laboratory services that employ molecular diagnostics and bioinformatics. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics used to detect pathogens in positive blood cultures. The company provides Acuitas MDRO gene test to identify the presence of antibiotic resistant genes for high-risk patients quickly and with high sensitivity and specificity; and Acuitas Lighthouse MDRO management system, which offers epidemiological typing, tracking, and trending to inform infection control, surveillance, and antibiotic stewardship decision makers. In addition, it offers Acuitas whole genome sequence analysis for transmission investigations and epidemiology research. OpGen, Inc. has a strategic collaboration with Hitachi High-Technologies Corporation to commercialize its genome mapping technology for mapping, assembly, and analysis of human DNA. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.